Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06215716




Registration number
NCT06215716
Ethics application status
Date submitted
6/12/2023
Date registered
22/01/2024
Date last updated
16/10/2024

Titles & IDs
Public title
A Study Evaluating Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Secondary ID [1] 0 0
AK-US-001-0105
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
NASH with Fibrosis 0 0
MASH with Fibrosis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Diet and Nutrition 0 0 0 0
Obesity
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Efruxifermin
Treatment: Drugs - Placebo

Experimental: EFX 28 mg -

Experimental: EFX 50 mg -

Placebo comparator: Placebo -


Treatment: Drugs: Efruxifermin
Administered by subcutaneous injection

Treatment: Drugs: Placebo
Administered by subcutaneous injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Cohort 1 Only: Resolution of NASH/MASH and a = 1 stage improvement in fibrosis
Timepoint [1] 0 0
52 Weeks
Primary outcome [2] 0 0
Event-free survival
Timepoint [2] 0 0
240 Weeks
Secondary outcome [1] 0 0
Cohort 1 Only: Resolution of NASH/MASH and no worsening of fibrosis
Timepoint [1] 0 0
52 Weeks
Secondary outcome [2] 0 0
Cohort 1 Only: = 1 stage improvement in fibrosis and no worsening of steatohepatitis
Timepoint [2] 0 0
52 Weeks
Secondary outcome [3] 0 0
Change from baseline of non-invasive markers of liver fibrosis
Timepoint [3] 0 0
52 Weeks, 240 Weeks
Secondary outcome [4] 0 0
Change from baseline of non-invasive markers of liver fibrosis
Timepoint [4] 0 0
52 Weeks, 240 Weeks
Secondary outcome [5] 0 0
Change from baseline of non-invasive markers of liver fibrosis
Timepoint [5] 0 0
52 Weeks, 240 Weeks
Secondary outcome [6] 0 0
Change from baseline of markers of liver injury
Timepoint [6] 0 0
52 Weeks, 240 Weeks
Secondary outcome [7] 0 0
Change from baseline of markers of liver injury
Timepoint [7] 0 0
52 Weeks, 240 Weeks
Secondary outcome [8] 0 0
Change from baseline of lipoproteins
Timepoint [8] 0 0
52 Weeks, 240 Weeks
Secondary outcome [9] 0 0
Change from baseline of markers of insulin sensitivity and glycemic control
Timepoint [9] 0 0
52 Weeks, 240 Weeks
Secondary outcome [10] 0 0
Change from baseline of markers of insulin sensitivity and glycemic control
Timepoint [10] 0 0
52 Weeks, 240 Weeks
Secondary outcome [11] 0 0
Change from baseline of body weight (kg)
Timepoint [11] 0 0
52 Weeks, 240 Weeks
Secondary outcome [12] 0 0
To assess the safety and tolerability of EFX through the reporting of extent of exposure (weeks)
Timepoint [12] 0 0
52 Weeks, 240 Weeks
Secondary outcome [13] 0 0
To assess the safety and tolerability of EFX through the reporting of adverse events (severity of events)
Timepoint [13] 0 0
52 Weeks, 240 Weeks
Secondary outcome [14] 0 0
To assess the safety and tolerability of EFX through the reporting of adverse events (frequency of events)
Timepoint [14] 0 0
52 Weeks, 240 Weeks
Secondary outcome [15] 0 0
To assess the safety and tolerability of EFX through the reporting of abnormal clinical laboratory tests, ECGs, ultrasounds, vital sign assessments (number of patients)
Timepoint [15] 0 0
52 Weeks, 240 Weeks
Secondary outcome [16] 0 0
To assess the immunogenicity of EFX through the reporting of antidrug antibodies (number of patients)
Timepoint [16] 0 0
52 Weeks, 240 Weeks

Eligibility
Key inclusion criteria
* Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit.
* Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.
* Cohort 1: Biopsy-proven NASH/MASH. Must have had a liver biopsy obtained = 180 days prior to screening with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of = 4 with at least a score of 1 in each of the following NAS components:

* Steatosis (scored 0 to 3),
* Ballooning degeneration (scored 0 to 2), and
* Lobular inflammation (scored 0 to 3).
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.
* Presence of cirrhosis on liver biopsy (fibrosis stage 4).
* Type 1 or uncontrolled Type 2 diabetes.

Other inclusion and exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/11/2032
Actual
Sample size
Target
1650
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Akero Clinical Study Site - Broadmeadow
Recruitment hospital [2] 0 0
Akero Clinical Study Site - Westmead
Recruitment hospital [3] 0 0
Akero Clinical Study Site - Adelaide
Recruitment hospital [4] 0 0
Akero Clinical Study Site - Caulfield South
Recruitment hospital [5] 0 0
Akero Clinical Study Site - Epping
Recruitment hospital [6] 0 0
Akero Clinical Study Site - Heidelberg
Recruitment hospital [7] 0 0
Akero Clinical Study Site - Melbourne
Recruitment hospital [8] 0 0
Akero Clinical Study Site - Murdoch
Recruitment hospital [9] 0 0
Akero Clinical Study Site - Perth
Recruitment postcode(s) [1] 0 0
2292 - Broadmeadow
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3162 - Caulfield South
Recruitment postcode(s) [5] 0 0
3076 - Epping
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment postcode(s) [8] 0 0
6150 - Murdoch
Recruitment postcode(s) [9] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New Mexico
Country [19] 0 0
United States of America
State/province [19] 0 0
New York
Country [20] 0 0
United States of America
State/province [20] 0 0
North Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oregon
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
South Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
Argentina
State/province [30] 0 0
Buenos Aires
Country [31] 0 0
Argentina
State/province [31] 0 0
Distrito Federal
Country [32] 0 0
Canada
State/province [32] 0 0
Alberta
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
France
State/province [35] 0 0
Alpes-Maritimes
Country [36] 0 0
France
State/province [36] 0 0
Bas-Rhin
Country [37] 0 0
France
State/province [37] 0 0
Haute-Vienne
Country [38] 0 0
France
State/province [38] 0 0
Hauts-de-Seine
Country [39] 0 0
France
State/province [39] 0 0
Ile-de-France
Country [40] 0 0
France
State/province [40] 0 0
Lorraine
Country [41] 0 0
France
State/province [41] 0 0
Maine-et-Loire
Country [42] 0 0
France
State/province [42] 0 0
Occitanie
Country [43] 0 0
France
State/province [43] 0 0
Provence Alpes Cote d'Azur
Country [44] 0 0
France
State/province [44] 0 0
Provence-Alpes-Côte d'Azur
Country [45] 0 0
France
State/province [45] 0 0
Rhone-Alpes
Country [46] 0 0
France
State/province [46] 0 0
Yvelines, Île-de-France
Country [47] 0 0
Germany
State/province [47] 0 0
Bayern
Country [48] 0 0
Germany
State/province [48] 0 0
Hessen
Country [49] 0 0
Germany
State/province [49] 0 0
Rheinland-Pfalz
Country [50] 0 0
Germany
State/province [50] 0 0
Sachsen
Country [51] 0 0
Germany
State/province [51] 0 0
Saxony
Country [52] 0 0
Germany
State/province [52] 0 0
Schleswig-Holstein
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
India
State/province [54] 0 0
Delhi
Country [55] 0 0
India
State/province [55] 0 0
Gujarat
Country [56] 0 0
India
State/province [56] 0 0
Kerala
Country [57] 0 0
India
State/province [57] 0 0
Maharashtra
Country [58] 0 0
India
State/province [58] 0 0
Rajasthan
Country [59] 0 0
India
State/province [59] 0 0
Tamil Nadu
Country [60] 0 0
India
State/province [60] 0 0
Telangana
Country [61] 0 0
India
State/province [61] 0 0
Uttar Pradesh
Country [62] 0 0
India
State/province [62] 0 0
West Bengal
Country [63] 0 0
Israel
State/province [63] 0 0
Central District
Country [64] 0 0
Israel
State/province [64] 0 0
Haifa District
Country [65] 0 0
Israel
State/province [65] 0 0
Northern District
Country [66] 0 0
Israel
State/province [66] 0 0
Jerusalem
Country [67] 0 0
Israel
State/province [67] 0 0
Tel Aviv
Country [68] 0 0
Italy
State/province [68] 0 0
Foggia
Country [69] 0 0
Italy
State/province [69] 0 0
Bologna
Country [70] 0 0
Italy
State/province [70] 0 0
Messina
Country [71] 0 0
Italy
State/province [71] 0 0
Milan
Country [72] 0 0
Italy
State/province [72] 0 0
Napoli
Country [73] 0 0
Italy
State/province [73] 0 0
Novara
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Daegu Gwang'yeogsi [Taegu-Kwangyokshi]
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Gyeonggi-Do
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Gyeonggi-do
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Gyeonggido [Kyonggi-do]
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Gyeongsangbugdo [Kyongsangbuk-do]
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
Country [80] 0 0
Poland
State/province [80] 0 0
Dolnoslaskie
Country [81] 0 0
Poland
State/province [81] 0 0
Malopolskie
Country [82] 0 0
Poland
State/province [82] 0 0
Mazowieckie
Country [83] 0 0
Poland
State/province [83] 0 0
Pomorskie
Country [84] 0 0
Poland
State/province [84] 0 0
Slaskie
Country [85] 0 0
Poland
State/province [85] 0 0
Wielkopolskie
Country [86] 0 0
Poland
State/province [86] 0 0
Lódzkie
Country [87] 0 0
Puerto Rico
State/province [87] 0 0
Manati
Country [88] 0 0
Puerto Rico
State/province [88] 0 0
San Juan
Country [89] 0 0
Spain
State/province [89] 0 0
Barcelona
Country [90] 0 0
Spain
State/province [90] 0 0
Cantabria
Country [91] 0 0
Spain
State/province [91] 0 0
Madrid
Country [92] 0 0
Spain
State/province [92] 0 0
València
Country [93] 0 0
Spain
State/province [93] 0 0
Sevilla
Country [94] 0 0
Switzerland
State/province [94] 0 0
Solothurn
Country [95] 0 0
Switzerland
State/province [95] 0 0
Bern
Country [96] 0 0
Switzerland
State/province [96] 0 0
Sankt Gallen
Country [97] 0 0
Taiwan
State/province [97] 0 0
Changhua
Country [98] 0 0
Taiwan
State/province [98] 0 0
Taichung
Country [99] 0 0
Taiwan
State/province [99] 0 0
Tainan
Country [100] 0 0
Taiwan
State/province [100] 0 0
Taipei
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taoyuan
Country [102] 0 0
Turkey
State/province [102] 0 0
Ankara
Country [103] 0 0
Turkey
State/province [103] 0 0
Izmir
Country [104] 0 0
Turkey
State/province [104] 0 0
Bursa
Country [105] 0 0
Turkey
State/province [105] 0 0
Rize
Country [106] 0 0
United Kingdom
State/province [106] 0 0
England

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Akero Therapeutics, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).

The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Trial website
https://clinicaltrials.gov/study/NCT06215716
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Akero Study Director
Address 0 0
Country 0 0
Phone 0 0
650-487-6488
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06215716